Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Design, Synthesis, and Structure-Activity Relationships of Thiazole Analogs as Anticholinesterase Agents for Alzheimer's Disease.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • المصدر:
      Publisher: MDPI Country of Publication: Switzerland NLM ID: 100964009 Publication Model: Electronic Cited Medium: Internet ISSN: 1420-3049 (Electronic) Linking ISSN: 14203049 NLM ISO Abbreviation: Molecules Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: Basel, Switzerland : MDPI, c1995-
    • الموضوع:
    • نبذة مختصرة :
      Dementia is a neurological condition commonly correlated with Alzheimer's disease (AD), and it is seen with many other central nervous system (CNS) disorders. The restricted number of medications is not appropriate to offer enough relief to enhance the quality of life of patients suffering from this symptom; thus, all therapeutic choices should be carefully assessed. In this study, new thiazolylhydrazone derivatives ( 2a - 2l ) were designed and synthesized based on the cholinergic hypothesis. Their chemical structures were confirmed by 1 H NMR, 13 C NMR, and HRMS spectrometric techniques. The ADME (absorption, distribution, metabolism, elimination) parameters of the synthesized compounds were predicted by using QikProp 4.8 software. It was concluded that all compounds presented satisfactory drug-like characteristics. Furthermore, their inhibitory activities against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) in vitro were also tested by modified the Ellman spectrophotometric method. According to the results, all compounds showed a weak inhibitory effect on BChE. On the other hand, most of the compounds ( 2a , 2b , 2d , 2e , 2g , 2i , and 2j ) had a certain AChE inhibitory activity, and the IC 50 values of them were calculated as 0.063 ± 0.003, 0.056 ± 0.002, 0.147 ± 0.006, 0.040 ± 0.001, 0.031 ± 0.001, 0.028 ± 0.001, and 0.138 ± 0.005 µM, respectively. Among these derivatives, compound 2i was found to be the most active agent in the series with an IC 50 value of 0.028 ± 0.001 µM, which indicated an inhibition profile at a similar rate as the reference drug, donepezil. The potential binding modes of compounds 2a , 2b , 2e , 2g , and 2i with AChE were investigated and compared with each other by the molecular docking studies. The results showed that these compounds were strongly bound up with the AChE enzyme active site with the optimal conformations.
    • References:
      JAMA. 2018 Jan 9;319(2):130-142. (PMID: 29318278)
      Eur J Med Chem. 2017 Jun 16;133:184-196. (PMID: 28388521)
      Sci Rep. 2017 Mar 03;7:42717. (PMID: 28256516)
      Eur J Med Chem. 2016 Nov 29;124:1026-1040. (PMID: 27783974)
      Eur J Med Chem. 2017 Sep 8;137:462-475. (PMID: 28624701)
      Neurosci Biobehav Rev. 2011 May;35(6):1397-409. (PMID: 21392524)
      J Biochem Mol Toxicol. 2009 Sep-Oct;23(5):303-8. (PMID: 19827033)
      ACS Chem Neurosci. 2013 Apr 17;4(4):547-65. (PMID: 23379636)
      Yao Xue Xue Bao. 2015 Jun;50(6):719-24. (PMID: 26521443)
      Lancet Neurol. 2008 Sep;7(9):812-26. (PMID: 18667359)
      Int J Mol Sci. 2013 Mar 11;14(3):5608-32. (PMID: 23478436)
      Molecules. 2019 Jun 28;24(13):. (PMID: 31261693)
      J Med Chem. 2012 Nov 26;55(22):10282-6. (PMID: 23035744)
      Science. 2002 Jul 19;297(5580):353-6. (PMID: 12130773)
      Bioorg Med Chem Lett. 2020 Mar 15;30(6):126985. (PMID: 32008906)
      Neuropathol Appl Neurobiol. 2013 Feb;39(1):51-68. (PMID: 23046210)
      Chem Biol Interact. 2010 Sep 6;187(1-3):10-22. (PMID: 20138030)
      J Med Chem. 2014 May 22;57(10):4302-12. (PMID: 24697335)
      Bioorg Med Chem. 2012 Dec 15;20(24):7214-22. (PMID: 23140986)
      J Enzyme Inhib Med Chem. 2018 Dec;33(1):794-803. (PMID: 29651884)
      Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):3-26. (PMID: 11259830)
      Curr Med Chem. 2011;18(32):4949-75. (PMID: 22050745)
      Bioorg Med Chem. 2015 Sep 1;23(17):5382-9. (PMID: 26260334)
      Biochim Biophys Acta. 2007 Aug;1768(8):1976-90. (PMID: 17433250)
      J Pharm Sci. 2001 Nov;90(11):1838-58. (PMID: 11745742)
      Bioorg Med Chem Lett. 2015 Nov 1;25(21):4848-4853. (PMID: 26159481)
      ACS Med Chem Lett. 2013 Sep 23;4(11):1091-6. (PMID: 24900610)
      J Enzyme Inhib Med Chem. 2018 Dec;33(1):37-57. (PMID: 29098902)
      Curr Alzheimer Res. 2008 Dec;5(6):525-32. (PMID: 19075578)
      Biochem Pharmacol. 1961 Jul;7:88-95. (PMID: 13726518)
      Bioorg Med Chem Lett. 2016 Nov 15;26(22):5387-5394. (PMID: 27789142)
      Bioorg Chem. 2019 Mar;84:41-50. (PMID: 30481645)
      Eur J Med Chem. 2003 Mar;38(3):223-32. (PMID: 12667689)
      Curr Neuropharmacol. 2013 May;11(3):315-35. (PMID: 24179466)
      Bioorg Med Chem Lett. 2011 May 15;21(10):2966-8. (PMID: 21458990)
      Bioorg Med Chem Lett. 2006 Sep 1;16(17):4657-60. (PMID: 16781151)
      Curr Opin Struct Biol. 2003 Aug;13(4):526-32. (PMID: 12948784)
      Eur J Med Chem. 2014 Jun 23;81:158-75. (PMID: 24836068)
      Anal Bioanal Chem. 2009 Jun;394(3):707-29. (PMID: 19184676)
      Arch Med Res. 2012 Nov;43(8):655-62. (PMID: 23142263)
      Molecules. 2019 Feb 28;24(5):. (PMID: 30823470)
      Molecules. 2018 Aug 14;23(8):. (PMID: 30110946)
      Drug Discov Today Technol. 2004 Dec;1(4):343-8. (PMID: 24981613)
      Adv Drug Deliv Rev. 2002 Mar 31;54(3):355-66. (PMID: 11922952)
      Front Chem. 2018 Mar 26;6:61. (PMID: 29632858)
      Neurochem Int. 2013 Apr;62(5):540-55. (PMID: 22982299)
      Yao Xue Xue Bao. 2014 Jun;49(6):813-8. (PMID: 25212025)
      Eur J Med Chem. 2016 Oct 4;121:864-879. (PMID: 26471320)
      Curr Pharm Des. 2006;12(6):705-17. (PMID: 16472161)
    • Grant Information:
      Anadolu University Scientific Projects Fund, Project No: 2005S046 Anadolu Üniversitesi
    • Contributed Indexing:
      Keywords: ADME parameters; Alzheimer’s disease; anticholinesterase enzyme activity; molecular docking; thiazole
    • الرقم المعرف:
      0 (Cholinesterase Inhibitors)
      0 (Thiazoles)
      8SSC91326P (Donepezil)
      EC 3.1.1.7 (Acetylcholinesterase)
      EC 3.1.1.8 (Butyrylcholinesterase)
    • الموضوع:
      Date Created: 20200923 Date Completed: 20210317 Latest Revision: 20240802
    • الموضوع:
      20240802
    • الرقم المعرف:
      PMC7570694
    • الرقم المعرف:
      10.3390/molecules25184312
    • الرقم المعرف:
      32962239